ArticleClinical interventions in aging2019
Long-term icariin treatment ameliorates cognitive deficits via CD4
Article in Clinical interventions in aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Icariin: from preclinical promise to clinical reality-a critical evidence-based assessment.Frontiers in pharmacology · 2026Review
- Targeting immunosenescence and inflammaging: advancing longevity research.Experimental & molecular medicine · 2025Review
- Benefit delayed immunosenescence by regulating CD4Aging cell · 2024Review
- A review on traditional Chinese medicine natural products and acupuncture intervention for Alzheimer's disease based on the neuroinflammatory.Chinese medicine · 2024Review
- Anti-aging effects of icariin and the underlying mechanisms: A mini-review.Aging medicine (Milton (N.S.W)) · 2024Review
- Icariin Improves Stress Resistance and Extends Lifespan inInternational journal of molecular sciences · 2023Article
- The role of natural flavonoids on neuroinflammation as a therapeutic target for Alzheimer's disease: a narrative review.Neural regeneration research · 2023Review
- Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future.Signal transduction and targeted therapy · 2023Review
- Icariin Ameliorates Alzheimer's Disease Pathology by Alleviating Myelin Injury in 3 × Tg-AD Mice.Neurochemical research · 2022Article
- HIF-1 signalling pathway was identified as a potential new pathway for Icariin's treatment against Alzheimer's disease based on preclinical evidence and bioinformatics.Frontiers in pharmacology · 2022Article
- Beneficial effects of natural flavonoids on neuroinflammation.Frontiers in immunology · 2022Review
- Licochalcone A improves the cognitive ability of mice by regulating T- and B-cell proliferation.Aging · 2021Article
- Flavonoids as an Intervention for Alzheimer's Disease: Progress and Hurdles Towards Defining a Mechanism of Action.Brain plasticity (Amsterdam, Netherlands) · 2021Review
- Xueshuantong Improves Functions of Lymphatic Ducts and Modulates Inflammatory Responses in Alzheimer's Disease Mice.Frontiers in pharmacology · 2021Article
- Article
- Rutaecarpine may improve neuronal injury, inhibits apoptosis, inflammation and oxidative stress by regulating the expression of ERK1/2 and Nrf2/HO-1 pathway in rats with cerebral ischemia-reperfusion injury.Drug design, development and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.